ES2663517T3 - Compuestos terapéuticos de isoxazol - Google Patents
Compuestos terapéuticos de isoxazol Download PDFInfo
- Publication number
- ES2663517T3 ES2663517T3 ES08828742.0T ES08828742T ES2663517T3 ES 2663517 T3 ES2663517 T3 ES 2663517T3 ES 08828742 T ES08828742 T ES 08828742T ES 2663517 T3 ES2663517 T3 ES 2663517T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- compound
- independently
- aryl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 44
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title description 2
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 125000003118 aryl group Chemical group 0.000 claims abstract description 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000001257 hydrogen Substances 0.000 claims abstract description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 15
- 125000005843 halogen group Chemical group 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 11
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 9
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 8
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 7
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 7
- 239000011593 sulfur Substances 0.000 claims abstract description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract description 4
- 229910003827 NRaRb Inorganic materials 0.000 claims abstract description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims abstract description 3
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 21
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 230000003920 cognitive function Effects 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 206010019196 Head injury Diseases 0.000 claims 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- -1 -OH Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 238000007833 oxidative deamination reaction Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- SNZSSCZJMVIOCR-UHFFFAOYSA-N 7-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1N2 SNZSSCZJMVIOCR-UHFFFAOYSA-N 0.000 description 1
- 229910014585 C2-Ce Inorganic materials 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000009109 downstream regulation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96820507P | 2007-08-27 | 2007-08-27 | |
| US968205P | 2007-08-27 | ||
| PCT/US2008/074353 WO2009029632A1 (en) | 2007-08-27 | 2008-08-26 | Therapeutic isoxazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2663517T3 true ES2663517T3 (es) | 2018-04-13 |
Family
ID=40387754
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17204892T Active ES2748599T3 (es) | 2007-08-27 | 2008-08-26 | Compuestos terapéuticos de isoxazol |
| ES08828742.0T Active ES2663517T3 (es) | 2007-08-27 | 2008-08-26 | Compuestos terapéuticos de isoxazol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17204892T Active ES2748599T3 (es) | 2007-08-27 | 2008-08-26 | Compuestos terapéuticos de isoxazol |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US8222243B2 (OSRAM) |
| EP (2) | EP3311813B1 (OSRAM) |
| JP (3) | JP5718053B2 (OSRAM) |
| KR (2) | KR101669432B1 (OSRAM) |
| CN (2) | CN104072489B (OSRAM) |
| AU (2) | AU2008293542B9 (OSRAM) |
| CA (2) | CA2974477C (OSRAM) |
| ES (2) | ES2748599T3 (OSRAM) |
| IL (3) | IL203910A (OSRAM) |
| MX (1) | MX2010002258A (OSRAM) |
| WO (1) | WO2009029632A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101370280B1 (ko) | 2005-07-26 | 2014-03-06 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | Ｃｏｍｔ 억제제로서의 니트로카테콜 유도체 |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| US8524746B2 (en) | 2007-01-31 | 2013-09-03 | Bial-Portela & Ca., S.A. | Dosage regimen for COMT inhibitors |
| KR101669432B1 (ko) | 2007-08-27 | 2016-10-26 | 다트 뉴로사이언스 (케이만) 엘티디. | 치료적 이속사졸 화합물 |
| RU2010139315A (ru) | 2008-03-17 | 2012-04-27 | Биал - Портела Энд Ка., С.А. (Pt) | Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола |
| DE102009041241A1 (de) | 2009-09-11 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102009041242A1 (de) | 2009-09-11 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
| MX340360B (es) | 2009-04-01 | 2016-07-07 | Bial-Portela & Ca S A | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. |
| WO2011076725A1 (en) * | 2009-12-21 | 2011-06-30 | Bayer Cropscience Ag | Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| CN102229606B (zh) * | 2011-06-03 | 2014-07-02 | 浙江工业大学 | 含异噁唑杂环的2-甲基苯并呋喃类衍生物及制备与应用 |
| CN102229603B (zh) * | 2011-06-03 | 2014-07-02 | 浙江工业大学 | 含三唑杂环的2-甲基苯并呋喃类化合物及其制备与应用 |
| EA201490228A1 (ru) | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
| WO2013066839A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| KR20140097459A (ko) | 2011-11-28 | 2014-08-06 | 노파르티스 아게 | 신규 트리플루오로메틸-옥사디아졸 유도체 및 질환의 치료에서의 그의 용도 |
| JP6456143B2 (ja) | 2011-12-13 | 2019-01-23 | ノヴィファーマ，エス．アー． | カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 |
| RU2668073C2 (ru) | 2013-03-14 | 2018-09-26 | Дарт Нейросайенс (Кайман) Лтд. | Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4 |
| BR112015022202A2 (pt) | 2013-03-14 | 2017-07-18 | Dart Neuroscience Cayman Ltd | compostos substituídos de naftiridina e quinolina como inibidores da mao |
| CN104016938B (zh) * | 2014-05-28 | 2016-08-17 | 浙江工业大学 | 一种含苯硒基的噁二唑类化合物及其制备与应用 |
| CN104016939B (zh) * | 2014-05-28 | 2016-06-15 | 浙江工业大学 | 一种2-亚乙基-3-乙酰基-1,3,4-噁二唑类化合物及其制备与应用 |
| CA2960386A1 (en) * | 2014-09-17 | 2016-03-24 | Dart Neuroscience (Cayman) Ltd. | Mao-b inhibitors and rehabilitation |
| JP2018500300A (ja) | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| WO2016179434A1 (en) | 2015-05-05 | 2016-11-10 | Dart Neuroscience, Llc | Systems and methods for cognitive testing |
| UY37623A (es) * | 2017-03-03 | 2018-09-28 | Syngenta Participations Ag | Derivados de oxadiazol tiofeno fungicidas |
| WO2018177993A1 (de) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazole zur bekämpfung von arthropoden |
| BR112019022137A2 (pt) | 2017-05-04 | 2020-05-12 | Basf Se | Usos de compostos, compostos da fórmula i, composição agroquímica e método para combater fungos nocivos fitopatogênicos |
| MX2020006596A (es) * | 2017-12-22 | 2020-09-10 | Bayer Ag | Hidroxiisoxazolinas y derivados de estos. |
| US10902558B2 (en) * | 2018-05-18 | 2021-01-26 | Gopro, Inc. | Multiscale denoising of raw images with noise estimation |
| US10853215B2 (en) * | 2018-09-10 | 2020-12-01 | Microsoft Technology Licensing, Llc | Intelligent configuration management of user devices |
| WO2024187126A1 (en) * | 2023-03-09 | 2024-09-12 | Aquinnah Pharmaceuticals, Inc. | Inhibitors of tdp-43 and tau aggregation |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB935523A (en) * | 1961-06-17 | 1963-08-28 | Acraf | New sulphamido-oxadiazoles |
| GB1051322A (OSRAM) * | 1967-08-09 | |||
| US3995048A (en) * | 1975-10-20 | 1976-11-30 | Sandoz, Inc. | Isoxazolyl benzamides useful as tranquilizers and sleep-inducers |
| AU576868B2 (en) | 1984-06-11 | 1988-09-08 | E.I. Du Pont De Nemours And Company | Thiophene and pyridine sulfonamides |
| JPS6183181A (ja) * | 1984-06-11 | 1986-04-26 | イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− | 除草剤性チオフエンスルホンアミド類およびピリジンスルホンアミド類 |
| DE3602016A1 (de) | 1985-12-05 | 1987-06-11 | Bayer Ag | Pyri(mi)dyl-oxy- und thio-benzoesaeure-derivate |
| DD265317A5 (de) * | 1985-12-05 | 1989-03-01 | Bayer Ag,De | Herbizide und pflanzenwuchsregulierende mittel |
| US5204482A (en) | 1988-07-28 | 1993-04-20 | Hoffman-Laroche Inc. | Compounds for treating and preventing cognitive diseases and depression and methods of making same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5047554A (en) | 1989-04-18 | 1991-09-10 | Pfizer Inc. | 3-substituted-2-oxindole derivatives |
| DE3929233A1 (de) * | 1989-09-02 | 1991-03-07 | Bayer Ag | 5-heterocyclyl-pyridin-3-carbon-benzylamide und -anilide |
| DE4126937A1 (de) | 1991-08-10 | 1993-02-11 | Basf Ag | Salicyl(thio)etherderivate, verfahren und zwischenprodukte zu ihrer herstellung |
| GB2265371A (en) * | 1992-03-06 | 1993-09-29 | Shell Int Research | Isoxazole compounds |
| US5246914A (en) * | 1992-08-07 | 1993-09-21 | Basf Aktiengesellschaft | Salicyloyl (thio)ether derivatives, their preparation and intermediates for their preparation |
| WO1996025405A1 (en) * | 1995-02-13 | 1996-08-22 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
| US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| AU3297397A (en) * | 1996-06-06 | 1998-01-05 | E.I. Du Pont De Nemours And Company | Herbicidal pyridinyl and pyrazolylphenyl ketones |
| WO1998037068A1 (en) * | 1997-02-21 | 1998-08-27 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
| HUP0001434A3 (en) | 1997-04-16 | 2001-01-29 | Abbott Lab | 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds, pharmaceutical compouads thereof and process for their preparation |
| JPH11139975A (ja) * | 1997-08-26 | 1999-05-25 | Sankyo Co Ltd | Ａ型モノアミンオキシダーゼ阻害薬 |
| DE19743435A1 (de) | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| JP4385414B2 (ja) | 1997-10-13 | 2009-12-16 | アステラス製薬株式会社 | アミド若しくはアミン誘導体 |
| AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
| DE19904389A1 (de) * | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
| EP1172361A4 (en) | 1999-04-19 | 2002-05-08 | Shionogi & Co | SULFONAMIDE DERIVATIVES HAVING OXADIAZOLE CORES |
| AR025884A1 (es) | 1999-10-01 | 2002-12-18 | Takeda Pharmaceutical | Compuestos de amina ciclica, su produccion y su uso |
| US7291641B2 (en) * | 1999-10-11 | 2007-11-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| JP2003528107A (ja) * | 2000-03-22 | 2003-09-24 | メルク フロスト カナダ アンド カンパニー | Ｐｔｐ−１ｂ阻害薬としての硫黄置換アリールジフルオロメチルホスホン酸類 |
| AU4691601A (en) * | 2000-04-21 | 2001-11-12 | Shionogi & Co | Oxadiazole derivatives having anticancer effects |
| JP2001316378A (ja) * | 2000-04-28 | 2001-11-13 | Takeda Chem Ind Ltd | ベンズアミド誘導体およびその用途 |
| US6579880B2 (en) * | 2000-06-06 | 2003-06-17 | Ortho-Mcneil Pharmaceutical, Inc. | Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8 |
| EP1311505A2 (en) | 2000-08-21 | 2003-05-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
| WO2002017358A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| MXPA03002296A (es) * | 2000-09-15 | 2003-06-06 | Vertex Pharma | Isoxazoles y su uso como inhibidores de erk. |
| IL157491A0 (en) | 2001-02-21 | 2004-03-28 | Nps Pharmeceuticals Inc | Heteropolycyclic compounds and pharmaceutical compositions containing the same |
| WO2003000249A1 (en) * | 2001-06-26 | 2003-01-03 | Takeda Chemical Industries, Ltd. | Function regulator for retinoid relative receptor |
| PL366624A1 (en) | 2001-07-05 | 2005-02-07 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as mch selective antagonists |
| US6727264B1 (en) | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
| WO2003018585A1 (en) | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease |
| US6660736B2 (en) | 2002-03-27 | 2003-12-09 | Hoffmann-La Roche Inc. | Phthalimido derivatives and a process for their preparation |
| TW200400035A (en) * | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
| US7329401B2 (en) * | 2002-04-15 | 2008-02-12 | The Regents Of The University Of California | Cyclooxygenase-2 selective agents useful as imaging probes and related methods |
| AU2003222648A1 (en) * | 2002-05-13 | 2003-12-02 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| BR0313371A (pt) * | 2002-08-02 | 2005-07-05 | Argenta Discovery Ltd | Composto, uso de um composto e método de tratamento de doença |
| ATE463739T1 (de) | 2002-08-19 | 2010-04-15 | Helicon Therapeutics Inc | Screening-verfahren für kognitive erweiterungsvorrichtungen |
| TW200406152A (en) * | 2002-08-30 | 2004-05-01 | Syngenta Participations Ag | 4-(3,3-Dihalo-allyloxy) phenol derivatives having pesticidal properties |
| SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
| EP1611112B1 (en) | 2003-02-11 | 2012-08-22 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| EP1622872A1 (en) * | 2003-03-28 | 2006-02-08 | Pfizer Products Inc. | 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity |
| DE10315571A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Pyrazolverbindungen |
| WO2004089367A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
| JPWO2005004021A1 (ja) | 2003-07-07 | 2006-08-17 | 富士通株式会社 | サービス提供装置、方法及びプログラム |
| US7199149B2 (en) | 2003-10-01 | 2007-04-03 | Bristol Myers Squibb Company | Monocyclic and bicyclic lactams as factor Xa inhibitors |
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| US7037927B2 (en) | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| ZA200605247B (en) * | 2003-12-15 | 2007-10-31 | Japan Tobacco Inc | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof |
| CN100584840C (zh) | 2004-01-05 | 2010-01-27 | 阿斯利康(瑞典)有限公司 | 取代杂环化合物及其应用 |
| CN102558082B (zh) | 2004-03-05 | 2015-09-30 | 日产化学工业株式会社 | 异噁唑啉取代苯甲酰胺化合物的制备中间体 |
| TW200538098A (en) | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| JP2008503446A (ja) * | 2004-05-06 | 2008-02-07 | プレキシコン，インコーポレーテッド | Ｐｄｅ４ｂ阻害剤及びその使用 |
| US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US20080138282A1 (en) * | 2004-06-03 | 2008-06-12 | The Trustees Of Columbia University In The City Of New York | Radiolabeled Arylsulfonyl Compounds and Uses Thereof |
| AU2005263592A1 (en) * | 2004-07-20 | 2006-01-26 | Siena Biotech S.P.A | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| GB0418267D0 (en) * | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
| US7338967B2 (en) | 2004-09-10 | 2008-03-04 | Syngenta Limited | Substituted isoxazoles as fungicides |
| RS20070076A (sr) | 2004-10-29 | 2008-09-29 | Astrazeneca Ab., | Novi derivati sulfonamida kao modulatori glukokortikoidnog receptora za lečenje zapaljenskih bolesti |
| JP2008522978A (ja) * | 2004-12-07 | 2008-07-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | ３，６−ビシクロライド |
| JP2008526999A (ja) * | 2005-01-19 | 2008-07-24 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病治療用ベータ−セクレターゼインヒビターとして活性な置換へテロ環含有三級カルビナミン |
| GB0504103D0 (en) | 2005-02-28 | 2005-04-06 | Syngenta Ltd | Novel method |
| JP2006316054A (ja) * | 2005-04-15 | 2006-11-24 | Tanabe Seiyaku Co Ltd | 高コンダクタンス型カルシウム感受性ｋチャネル開口薬 |
| WO2006134481A1 (en) * | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
| US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| EP1910308B1 (en) | 2005-06-27 | 2014-09-03 | Exelixis Patent Company LLC | Imidazole based lxr modulators |
| US20090325924A1 (en) * | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| JP2009509932A (ja) | 2005-09-07 | 2009-03-12 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| DOP2006000210A (es) * | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| WO2007043401A1 (ja) * | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびそれを含有する医薬組成物 |
| GB0603041D0 (en) * | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| JP5503874B2 (ja) | 2006-02-28 | 2014-05-28 | ダート ニューロサイエンス （ケイマン） エルティーディー | 治療化合物 |
| WO2007103456A2 (en) * | 2006-03-06 | 2007-09-13 | Trimeris, Inc. | Piperazine and piperidine biaryl derivatives |
| WO2008023248A2 (en) | 2006-08-24 | 2008-02-28 | Wockhardt Research Centre | Novel macrolides and ketolides having antimicrobial activity |
| US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| JP5427769B2 (ja) | 2007-03-30 | 2014-02-26 | サノフイ | Ｐｇｄｓ阻害剤としてのピリミジンヒドラジド化合物 |
| KR101669432B1 (ko) | 2007-08-27 | 2016-10-26 | 다트 뉴로사이언스 (케이만) 엘티디. | 치료적 이속사졸 화합물 |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
-
2008
- 2008-08-26 KR KR1020157012712A patent/KR101669432B1/ko not_active Expired - Fee Related
- 2008-08-26 ES ES17204892T patent/ES2748599T3/es active Active
- 2008-08-26 CN CN201410184138.1A patent/CN104072489B/zh not_active Expired - Fee Related
- 2008-08-26 CN CN200880110343.6A patent/CN101820764B/zh not_active Expired - Fee Related
- 2008-08-26 EP EP17204892.8A patent/EP3311813B1/en not_active Not-in-force
- 2008-08-26 CA CA2974477A patent/CA2974477C/en not_active Expired - Fee Related
- 2008-08-26 AU AU2008293542A patent/AU2008293542B9/en not_active Ceased
- 2008-08-26 CA CA2696609A patent/CA2696609C/en not_active Expired - Fee Related
- 2008-08-26 EP EP08828742.0A patent/EP2182809B1/en not_active Not-in-force
- 2008-08-26 US US12/198,686 patent/US8222243B2/en not_active Expired - Fee Related
- 2008-08-26 MX MX2010002258A patent/MX2010002258A/es active IP Right Grant
- 2008-08-26 KR KR1020107006239A patent/KR101567454B1/ko not_active Expired - Fee Related
- 2008-08-26 JP JP2010523095A patent/JP5718053B2/ja not_active Expired - Fee Related
- 2008-08-26 ES ES08828742.0T patent/ES2663517T3/es active Active
- 2008-08-26 WO PCT/US2008/074353 patent/WO2009029632A1/en not_active Ceased
-
2010
- 2010-02-11 IL IL203910A patent/IL203910A/en active IP Right Review Request
-
2012
- 2012-04-16 US US13/448,052 patent/US8921399B2/en not_active Expired - Fee Related
- 2012-07-05 US US13/542,358 patent/US9029397B2/en active Active
-
2013
- 2013-06-03 IL IL226702A patent/IL226702A/en active IP Right Grant
-
2014
- 2014-05-01 IL IL232406A patent/IL232406A/en active IP Right Grant
- 2014-05-26 AU AU2014202864A patent/AU2014202864B2/en not_active Ceased
-
2015
- 2015-03-13 JP JP2015050436A patent/JP2015110666A/ja not_active Withdrawn
- 2015-05-11 US US14/709,206 patent/US9650349B2/en not_active Expired - Fee Related
-
2016
- 2016-07-13 JP JP2016138293A patent/JP6250746B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-04 US US15/479,086 patent/US10053467B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2663517T3 (es) | Compuestos terapéuticos de isoxazol | |
| ES2235170T3 (es) | Enantiomero r de n-propargil-1-aminoindano para su tratamiento de diversas enfermedades y mesilato, esilato y sulfato del mismo. | |
| US11524935B2 (en) | Methods for treating attention-deficit/hyperactivity disorder | |
| KR101828934B1 (ko) | 양극성 장애의 치료방법 | |
| Löscher et al. | Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. | |
| CN103025326B (zh) | 治疗不安腿综合征的方法 | |
| CA2643235C (en) | Use of rasagiline for the treatment of multiple system atrophy | |
| US9827210B2 (en) | Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration | |
| US12258336B2 (en) | Preparation of seimicarbazide-sensitive amine oxidase inhibitor and use thereof | |
| KR20100014392A (ko) | 섬유근통 치료용 드록시도파 및 약학 조성물 | |
| CA2779442A1 (en) | Methods for treating fibromyalgia syndrome | |
| JP2011525185A5 (OSRAM) | ||
| US20090088449A1 (en) | 4-acylaminopyridine derivative mediated neurogenesis | |
| JP2005522445A (ja) | 注意欠陥過活動性障害（ａｄ／ｈｄ）の処置方法 | |
| EP3589322A1 (en) | Treatment of dementia with cannabinoid agonists | |
| US9907803B2 (en) | Methods for treating attention deficit hyperactivity disorder | |
| Tanaka et al. | Antidepressant-like Effects of Kynurenic Acid Analogues | |
| US20170112815A1 (en) | Betahistine for the treatment of neurodegenerative diseases | |
| JP2015516446A (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびガバペンチノイドを含む医薬組成物 | |
| Dunbar et al. | P. 2. a. 002 The potential of the nicotinic channel blocker tc-5214 as augmentation treatment in patients with major depression | |
| CA3084623C (en) | The use of 3-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)quinazolin-4(3h)- one in the treatment of post-traumatic stress disorder | |
| UY28712A1 (es) | Agentes terapéuticos | |
| MX2023001285A (es) | Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos. | |
| CN119947712A (zh) | 他西匹啶和cyp2d6抑制剂组合疗法 | |
| WO2021229583A1 (en) | Fused pyrazole and imidazole based compounds and use thereof as gli1 inhibitors |